News: Eli Lilly to Acquire Verve Therapeutics to Advance One-Time Cardiovascular Treatments - CRISPR Medicine
Eli Lilly announced today that it will acquire Verve Therapeutics for up to $1.3 billion to develop single-dose base-editing treatments for people with high cardiovascular risk.
News: Eli Lilly to Acquire Verve Therapeutics to Advance One-Time Cardiovascular Treatments - CRISPR Medicine Eli Lilly to Acquire Verve Therapeutics to Advance One-Time Cardiovascular Treatments Eli Lilly announced today that it will acquire Verve Therapeutics for up to $1.3 billion to develop single-dose base-editing treatments for people with high cardiovascular risk. By: Karen O'Hanlon Cohrt - Jun. 17, 2025 Eli Lilly and Verve Therapeutics announced today that Lilly will acquire Verve for up to $1.3 billion. Under the terms of the agreement, Lilly will commence a tender offer to acqui
Explore this link on the map →related reading
- Significantly Enhancing Adult Intelligence With Gene Editing May Be Possible — LessWronglesswrong.com
- Medical breakthroughs in 2025 - by Saloni Dattaniscientificdiscovery.dev
- FDA Approves First CRISPR Gene Editing Treatment for Sickle Cell Disease | Scientific Americanscientificamerican.com
- Going Founder Mode On Cancer - by Elliot Hershbergcenturyofbio.com
- Gene Genies: Inside The Revolutionary Biotech That Can Edit DNA Inside Living Humansforbes.com
- This baby boy was treated with the first personalized gene-editing drug | MIT Technology Reviewtechnologyreview.com
- Medicine's Endgamenotboring.co
- The current state and future directions of RNAi-based therapeutics | Nature Reviews Drug Discoverynature.com
- The 23andMe Deal - Cremieux Recueilcremieux.xyz
- Large NIH Grant Supports CRISPR-based Gene Therapy Development for Brain Diseases | Yale School of Medicinemedicine.yale.edu
- Curative gene therapies for rare diseases - PMCncbi.nlm.nih.gov
- Where are all the trillion dollar biotechs?ladanuzhna.xyz